MOL CANCER 润色咨询

Molecular Cancer

出版年份：2002 年文章数：971 投稿命中率： 开通期刊会员，数据随心看

出版周期：Irregular 自引率：2.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2022-12-22 wooshiwo 来自辽宁省

    偏重的研究方向：肿瘤
    经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2025-08-05 P拾荒者 来自浙江省

    偏重的研究方向：肿瘤微环境;肿瘤;Cancer
    经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2025-01-02 Dr医小小生 来自上海

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤微环境;Immunology;肿瘤
    经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2024-09-22 Dr医小小生 来自上海

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤微环境;肿瘤
    经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2024-03-10 1811e984f8m 来自安徽省

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤;肿瘤化疗
    经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。

    14

    展开14条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2024-11-30 ms2000001788822132 来自上海

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤
    经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2023-10-20 ms1000001749825166 来自江苏省

    很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2022-01-21 DDPP

    评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。

    21

    展开21条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2022-08-02 ms6000001160390657

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向：lncRNA
    经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊

    8

    展开8条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2276150, encodeId=3b8122e6150e6, content=偏重的研究方向：肿瘤微环境;肿瘤;Cancer<br>经验分享：头铁的我投了一篇综述，看看这周什么时候拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Aug 05 20:20:02 CST 2025, time=2025-08-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2246265, encodeId=e44d22462657a, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤微环境;Immunology;肿瘤<br>经验分享：格式初审的被打回来，现在要求上传未裁剪的wb图片以附加图形式上传了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Thu Jan 02 22:37:21 CST 2025, time=2025-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2226993, encodeId=4b84222699318, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤微环境;肿瘤<br>经验分享：近期投了两篇综述，一篇秒拒（大概2天），一篇送外审，3个审稿人提了40多建议，根据意见认真返修以后，很快接收了，整体用了两个多月，算是非常顺利的了。综述的投稿还是挺难的，文章的选题和质量应该都需要编辑中意的才有机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/5881b3b9f79895598de78bbb108aee49.jpg, createdBy=552e2021252, createdName=Dr医小小生, createdTime=Sun Sep 22 00:28:21 CST 2024, time=2024-09-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤;肿瘤化疗<br>经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=358, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2240112, encodeId=c97b224011256, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：这个期刊其实从2019年就开始存在很大争议，感觉很难投中，也不像传说中的那样期刊很水呀，反而觉得没有扎实的工作量基本不要来碰，会被秒拒😂<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:56:08 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1186775, encodeId=afae1186e75d9, content=评审项目时我们同行一般把他当做5-8分期刊看，但整体质量在逐年上升。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=260, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Fri Jan 21 12:13:05 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236138, encodeId=d7c4123613892, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：lncRNA<br>经验分享：这个期刊其实从2019年就开始存在很大争议，当年还没过10+，现在看来越来越明显，像很多名校都把MC这个杂志拉黑了，不给报销，不给晋升。中大内部也拉黑了这个期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0128257688, createdName=ms6000001160390657, createdTime=Tue Aug 02 12:22:03 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京)]
    2023-10-26 ms4000001583479348 来自北京

    终于接收啦 历经四个月。希望杂志越来越好吧。

    5

    展开5条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分